Search

Author/Creator Gooderham, Melinda

1. 309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. (25th January 2023)

Authors:
Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew 
Journal:
British journal of dermatology
Issue:
Volume 188(2023)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis. (25th January 2023)

Authors:
Gooderham, Melinda; Shi, Vivian Y; Wollenberg, Andreas; Thyssen, Jacob P; Torres, Tiago; Gil, Esther Garcia; Bardolet, Laia; Natalie, Chitra R; Atwater, Amber R; Zhao, Fangyi; Blauvelt, Andrew
Journal:
British journal of dermatology
Issue:
Volume 188(2023)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. (25th January 2023)

Authors:
Silverberg, Jonathan I; Gooderham, Melinda; Katoh, Norito; Aoki, Valeria; Pink, Andrew E; Binamer, Yousef; Wollenberg, Andreas
Journal:
British journal of dermatology
Issue:
Volume 188(2023)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 328 Understanding the impact of atopic dermatitis on patients: a large international, ethnically diverse survey-based qualitative study. (25th January 2023)

Authors:
Wollenberg, Andreas; Gooderham, Melinda; Katoh, Norito; Aoki, Valeria; Pink, Andrew E; Binamer, Yousef; Silverberg, Jonathan I
Journal:
British journal of dermatology
Issue:
Volume 188(2023)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Issue 1 (28th September 2019)

Authors:
Mease, Philip J; Smolen, Josef S; Behrens, Frank; Nash, Peter; Liu Leage, Soyi; Li, Lingnan; Tahir, Hasan; Gooderham, Melinda; Krishnan, Eswar; Liu-Seifert, Hong; Emery, Paul; Pillai, Sreekumar G; Helliwell, Philip S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79:Issue 1(2020)
Page Start:
123
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗